Press Releases

 
Press Releases
  Date Title and Summary View
Feb 25, 2015
REDWOOD CITY, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,900,000 shares of its common stock at a price to the public of $38.50 per share, before underwriting discounts, for gross proceeds of approximately $150 million. In ad...
Feb 24, 2015
REDWOOD CITY, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of up to $130,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Relypsa. In addition, Relypsa...
Feb 24, 2015
REDWOOD CITY, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 17, 2015, the compensation committee of the company's board of directors granted four new employees options to purchase an aggregate of 57,000 shares of the company's common stock with a per share exerci...
Feb 23, 2015
REDWOOD CITY, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the Cowen and Company 35th Annual Healthcare Conference on March 3, 2015 at 8:40 a.m. ET. To access the live webcasts and subsequent archived recordings of these pres...
Feb 4, 2015
REDWOOD CITY, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 2, 2015, the compensation committee of the company's board of directors granted nine new employees an option to purchase an aggregate of 41,400 shares of the company's common stock with a per share exerci...
Feb 2, 2015
REDWOOD CITY, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the 17th Annual BIO CEO & Investor Conference on February 10, 2015 at 9:00 a.m. ET. To access the live webcasts and subsequent archived recordings of these presentatio...
Jan 22, 2015
REDWOOD CITY, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board signif...
Jan 20, 2015
REDWOOD CITY, Calif., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2015, the compensation committee of the company's board of directors granted one new employee an option to purchase 1,200 shares of the company's common stock with a per share exercise price of $31.65...
Jan 9, 2015
REDWOOD CITY, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 2, 2015, the compensation committee of the company's board of directors granted new employee Stephen D. Harrison, the company's senior vice president and chief scientific officer, an option to purchase 75,...
Jan 5, 2015
FDA Not Currently Planning to Hold an Advisory Committee MeetingCompany to Host Webcasted Analyst Day in New York on January 8, 2015 REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action dat...
Page:
1
... NextLast
= add release to Briefcase